In the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON), patients with an acute myocardial infarction with ST-segment elevation underwent percutaneous coronary intervention with either a sirolimus-eluting stent or an uncoated stent. The use of the sirolimus-eluting stent was associated with significant reductions in the rate of target-vessel failure and the severity of in-stent late luminal loss. Patients with an acute myocardial infarction underwent percutaneous coronary intervention with either a sirolimus-eluting stent or an uncoated stent. The use of the sirolimus-eluting stent was associated with significant reductions in the rate of target-vessel failure and the severity of in-stent late luminal loss. The use of sirolimus-eluting coronary-artery stents significantly reduces the incidence of restenosis after percutaneous coronary intervention (PCI), as compared with the use of uncoated stents. 1 – 3 However, most randomized trials evaluating sirolimus-eluting stents have excluded patients with acute myocardial infarction with ST-segment elevation. Small series of patients with acute myocardial infarction have shown that the implantation of a sirolimus-eluting stent is associated with a low rate of restenosis. 4 , 5 In the Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction (STRATEGY) trial, the use of sirolimus-eluting stents reduced cardiovascular events, as compared with the . . .